Treatment strategies are applied to enhancement of performance and appearance
The desire to improve physical performance, mental capacity and appearance is an inherent human trait. 1 As a reflection of this, society places high values on certain physical and mental traits and shuns others. 2 Individuals with highly valued societal characteristics are rewarded
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Prospects
Enhancements are likely becoming more common and acceptable in the future. Increasing numbers of genetic enhancement strategies will be investigated in different animal models. Efficacy and safety of gene therapy technologies will be improved with the aim of developing clinically applicable approaches. Strategies to detect illegal use of genetic enhancement, such as gene doping, will be developed. Evaluation of ethical, societal and regulatory issues regarding genetic enhancement will be imperative before genetic enhancement can become a reality.
with position, respect and financial gain, and often have a variety of societal advantages.
With such high value placed on performance and appearance, it is not surprising that society accepts a variety of strategies to improve both. As an example, the use of botulinum toxin type A for facial enhancement is the most common cosmetic procedure currently undertaken in the United States. 3 Other examples of widely accepted approaches for appearance enhancement include use of drugs and hair follicle transplantation for hair loss and surgical procedures to reverse the appearance of aging or unwanted body fat. 3, 4 Coffee drinking, the most common form of mental enhancement, is essentially a drug delivery system for caffeine, as is cigarette smoking to deliver nicotine to the central nervous system. 1 Despite this common acceptance of physical and mental enhancement strategies, society draws the line at some strategies, either because the risk seems to be too high for what is considered a minor benefit, and/or the strategy per se is not acceptable. For example, erythropoietin (EPO) is acceptable for treatment of chronic anemia but is not accepted for improvement of endurance in sports. 5 Similarly, growth hormone (GH) is an appropriate treatment for short stature due to GH deficiency or Turner's syndrome, but not for use to become taller or stronger for social, esthetic or athletic reasons. 6 The challenge is where to delineate the line between 'disease' and 'enhancement,' an issue that is often difficult to resolve. For many ethicists, genetic therapies are of significant concern, in that they represent a slippery ethical slope ending in the acceptance of germ line therapies. 4, 7, 8 Gene therapy was originally designed to compensate for and/or treat genetic or acquired diseases such as cystic fibrosis, bleeding disorders, muscular dystrophies and cancer, 9 but gene therapy can also be employed for nontherapeutic purposes as an enhancement intervention. 1, 4 In the context that gene therapy is basically a delivery system for proteins, it is understandable that the technology of gene therapy is of concern regarding its use as 'enhancement therapy'. In this review, we focus on recent advances in the field and first discuss examples of gene therapy that can be used for performance enhancement, such as augmentation of oxygen carrying capacity and muscle mass or enhancing memory and cognition (Tables 1 and 2 ). We then review gene therapy strategies that can be employed for appearance enhancement, such as improving weight control and hair growth (Table 3) . Finally, we discuss the ethical and societal as well as safety issues involved in enhancement interventions.
Gene transfer is used to enhance endurance and muscle strength
The World Anti-Doping Agency defines gene and cell doping as 'the nontherapeutic use of genes, cells and genetic elements to enhance athletic performance.' 48 Gene doping is especially challenging, because of limitations in detection methods as the products of the transferred and endogenous genes are close to identical. 5, [49] [50] [51] [52] [53] [54] The areas involved in gene doping include enhancement of endurance and muscle strength (Table 1) .
Erythropoietin is a key regulator of erythrocyte production EPO is an acidic glycoprotein hormone, produced by the kidneys, with a molecular mass of 34 kDa. 50, 51 It is a key regulator of erythrocyte production with major functions in promoting erythroid differentiation and initiating hemoglobin synthesis. 55 Therapeutically, EPO is used to treat patients with severe anemia, such as patients with kidney failure, undergoing chemotherapy or with hereditary hemoglobin defects. 55 As has been widely reported in the media in conjunction with endurance bicycle racing, EPO protein has been extensively used to enhance performance. 5, [49] [50] [51] [52] [53] [54] An example of natural enhancement of physical performance by enhanced effect of EPO is the winner of two gold medals in cross-country skiing in 1964 Olympic Games, who had a naturally-occurring activating mutation in the EPOR gene leading to an increase in the amount of erythrocytes, and therefore, enhancement of endurance. 5 Gene transfer with EPO aims at delivering an additional copy of the EPO gene into the body to achieve stable protein expression in vivo, and therefore, eliminating frequent injections and the need to manufacture recombinant protein, exemplifying one of the main advantages of gene therapy. 12 EPO gene therapy has been conducted in several species including mice, rats and monkeys by systemic or local delivery by using vectors derived from adenovirus, 13 adeno-associated virus (AAV) [10] [11] [12] [13] [14] [15] [16] or lentivirus, 17, 18 by using plasmids alone or with adjunctive delivery systems [19] [20] [21] or by transplanting cells or tissues transduced with the EPO gene ex vivo. [22] [23] [24] [25] In experimental animals, depending on the delivery strategy, gene transfer resulted in increased levels of EPO and an increased hematocrit (percent of erythrocytes in blood) for an extended period of time varying from 2 weeks to 6 years. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In a human study in patients with chronic renal failure, EPO delivery was conducted by transplanting autologous dermal tissue transduced ex vivo by adenovirus encoding EPO resulting in increased EPO expression and reticulocyte levels. 23 Increased EPO expression and hematocrit lasted for 14 days in these patients. The decrease in EPO levels was associated with a dermal infiltrate of cytotoxic T cells and anti-EPO antibodies were detected 90 days after implantation.
While achieving stable expression is beneficial in many ways, adverse effects may result from sustained overexpression of EPO leading to excessive erythrocytosis and hepatic, renal, neuronal and muscular degeneration. 56 To circumvent these effects, controlled gene expression by using tetracycline or rapamycin-regulated AAV vectors and plasmids have been introduced. 10, 12, 14, 16 Detection of EPO misuse typically involves direct pharmacological approaches and indirect markers of erythropoiesis. 51, 55 While human recombinant protein produced in nonhuman cells can be detected based on the difference in isoelectric profiles as a result of speciesspecific post-translational modifications, means to detect EPO gene doping are limited. 55 A study describing detection of EPO in serum by isoelectric profile after delivery of AAV encoding EPO into skeletal muscle argues that genetic doping can be detected, at least in serum, and is likely due to cell-type dependent differences in post-translational modifications. 55 Enhancement gene therapy M Kiuru and RG Crystal Abbreviations: AAV, adeno-associated virus; Ad, adenovirus; EPO, erythropoietin; GH, growth hormone; IGF1, insulin-like growth factor 1; MSCs, mesenchymal stem cells.
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Vascular endothelial growth factor promotes blood vessel formation
Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein expressed as several isoforms functioning to promote formation of new blood vessels. 57 As VEGF gene therapy has shown beneficial effects on ischemic heart disease and peripheral arterial disease in animal models, 57 it theoretically could also potentiate supply of oxygen and nutrients to muscles, heart and other tissues in athletes. 5 As an example of performance enhancement, myocardial delivery of adenovirus carrying a VEGF isoform 121 transgene into rats resulted in a significant increase in exercise tolerance (Figure 1 ). In addition to Ad and AAV vectors encoding for VEGF, overexpression of VEGF gene has been demonstrated by using a zinc-finger DNA-binding transcription factor that increases the expression of all VEGF isoforms leading to enhancement of muscle regeneration and neovascularization. 58 VEGF gene therapy clinical trials have been carried out for peripheral vascular disease and coronary artery disease. 59 Although preclinical and clinical safety trials have been promising, the randomized controlled trials have not shown clinically relevant positive outcomes. Abbreviations: AAV, adeno-associated virus; Ad, adenovirus; GDNF, glial cell line-derived neurotrophic factor; Ob, obese; POMC, proopiomelanocortin; Shh, Sonic hedgehog.
Insulin-like growth factor 1 enhances muscle strength
Techniques to enhance muscle strength have stemmed from studies on degenerative muscle disorders, such as muscular dystrophies. 60, 61 Insulin-like growth factor 1 (IGF1) is a 70 amino-acid polypeptide critical in regulating the growth of muscle and other tissues and mediating many of the growth-promoting effects of GH. 62 The anabolic effects of IGF1 result from stimulation of protein synthesis, proliferation and differentiation of muscle satellite cells whereas the anti-catabolic effects include inhibition of muscle proteolysis and apoptosis.
26
IGF1 gene therapy by intramuscular injection of AAV 27, 61 or DNA electroporation 26 resulted in increased muscle mass and strength in mice and rats.
Growth hormone leads to muscle buildup
GH is a 191 amino-acid polypeptide functioning in the regulation of postnatal somatic growth. 62 GH is a key regulator of a cascade leading to buildup of muscle and reducing fat. 62 In addition to being used therapeutically, GH is misused for doping in sports. Recombinant GH protein constitutes a problem in monitoring against doping, as it is not easily detectable due to limited glycosylation, although it may be detected based on the absence of a mixture of variations and fragments of the protein typical of the endogenous GH. 50 To avoid frequent injections and costly treatment by using recombinant GH protein, gene therapy for GH treatment is being developed. The same methodology may, however, be used for gene doping. The principle of AAV-mediated GH expression was demonstrated by myocardial gene delivery, which improved cardiac function and reduced pathologic remodeling post-myocardial infarction. 28 Various other candidate genes to increase muscle strength have also been studied Other candidate molecules for increasing muscle strength by gene therapy include myostatin, peroxisome proliferator-activated receptor-d (PPARd) and peroxisome proliferator-activated receptor-g co-activator-1 a and b (PGC-1 a and b) . Myostatin belongs to the transforming growth factor b superfamily of signaling cytokines. 63 It is synthesized as a 375 amino-acid precursor protein that is further processed giving rise to a 26 kDa mature protein.
Myostatin is expressed almost exclusively in skeletal muscle cells and functions as a negative regulator of muscle growth. Targeted disruption of the myostatin gene in mice results in doubling of muscle mass. 64 Similarly, a loss-of-function mutation in a human patient was reported to lead to muscle hypertrophy. 64 Strategies to inhibit myostatin signaling include neutralizing antibodies against myostatin, blocking myostatin binding to its receptor either by follistatin, mutant activin type 2 receptor proteins, or myostatin propeptide, or silencing myostatin gene by RNAi. These approaches have resulted in amplification of muscle fiber number and thickness leading to an increase in skeletal muscle mass or body mass. 29, 65 Recently, a gene therapy strategy for inhibition of myostatin was demonstrated by AAVmediated expression of mutated myostatin propeptide in animal models of muscular dystrophies leading to increased muscle mass and absolute force. 30 PPARd plays an important role in adaptive response of skeletal muscle to environmental changes by controlling the myofiber type composition and driving the formation of functional type I muscle fibers (oxidative and fatigueresistant slow fibers). 60, 66 Transgenic mice with targeted expression of an activated form of PPARd showed increased running capacity and endurance as well as resistance to obesity. 60 Corresponding results were obtained in wild-type mice with a PPARd agonist. 60 Similar effects on myofiber composition and endurance have been reported in transgenic mice with overexpression of PGC-1 a and b. 60, 67 Interestingly, PPARd gene polymorphisms were recently found to be associated with cardiorespiratory fitness and plasma lipid responses to endurance training in humans. 68 Clinical trials aiming at increasing muscle strength have been conducted in patients affected with inherited muscle dystrophies. Intramuscular delivery of full-length dystrophin cDNA or AAV encoding partial dystrophin or intravenous delivery of antisense oligos that introduce skipping of exons harboring frameshift mutations in dystrophin gene have resulted in weak expression of dystrophin in muscle biopsies in these patients.
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Intracranial gene delivery is used to improve memory and learning Gene therapy strategies have also been employed to enhance mental performance, such as memory and cognition (Table 2 ). Glucocorticoids, secreted by the adrenal gland during stress, may impair acquisition and retrieval of spatial memory and can either attenuate or improve consolidation. 31 Estrogen, by contrast, enhances spatial memory performance and can inhibit the harmful effects of glucocorticoids. 70 Using intracerebral delivery of a herpes simplex virus 1 vector encoding a chimeric receptor for estrogen and glucocorticoids, enhancement of spatial memory was observed in wildtype male rats. 
Enhancement gene therapy M Kiuru and RG Crystal
Learning and memory have been postulated to be encoded by specific circuits within cortical areas. 32 The neural network theories predict that activating small fraction of the neurons in a circuit can activate the circuit, and therefore, improve learning. This was achieved by herpes simplex virus 1-mediated delivery of protein kinase C into postrhinal cortex in rats, which resulted in transgene expression and improved learning rate and accuracy of visual object discrimination for 2-4 weeks. 32 Gene therapy provides a means to control weight, height and hair growth
As do cosmetic surgery and nonsurgical approaches to enhance skin and soft tissue and shape of the body, gene therapy strategies have provided means to enhance appearance. The main areas of enhancement by gene therapy include weight control and skin/hair enhancements ( Table 3) .
Modulation of leptin expression results in weight loss
Currently available approaches for treating obesity are characterized by poor compliance, transient effectiveness and undesirable side effects. 71 There are several genes that have been linked to weight control and tested for therapeutic potential by gene therapy, including leptin, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] proopiomelanocortin (POMC) [43] [44] [45] and glial cell line-derived neurotrophic factor (GDNF). 46 The interplay between appetite-stimulating and appetite-inhibiting factors is crucial for the management of energy intake and expenditure. 71 Leptin, produced by the adipose tissue and the hypothalamus, has a key role in restraining overeating by modulating the interaction between appetite-stimulating and appetite-inhibiting factors and by increasing thermogenic energy expenditure. 71 By contrast, an opposing hormone ghrelin, produced by the stomach and hypothalamus, stimulates appetite. Mediators involved in the interplay include POMC, neuropeptide Y, g-aminobutyric acid and agoutirelated peptide. After initial reports on using adenovirus vectors for leptin gene therapy, AAV administration was shown to result in elevated plasma leptin levels and reduced body weight for extended periods of time. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] In most of these studies, potential pleiotropic effects of leptin on other organs, including immune system, bone, blood vessels, kidneys and pancreas were circumvented by restricting AAV-mediated expression of leptin to the brain by using an intracerebroventricular route of administration. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] AAV-mediated expression of leptin by intracerebroventricular administration inhibited fat accumulation and food intake for periods equivalent to the lifespan of a rodent in obese and wild-type mice, as well as in prepubertal and adult wild-type rats. 33 Other candidates for weight control by gene therapy include POMC and GDNF. 71 POMC is a prehormone of melanocortins that play a central role in the regulation of energy balance and glucose metabolism. 71 AAVmediated expression of POMC by central nervous system delivery in rats resulted in a decrease in body weight and adiposity for a period of 40 days. 43, 44 GDNF is a neurotrophic factor that promotes the survival and maturation of central dopaminergic neurons and when administered to the central nervous system, causes weight loss possibly due to increased locomotive activity. 46 AAV-mediated GDNF expression in the hypothalamus of young and aged rats resulted in weight loss associated with decreased food intake and increased energy expenditure. 46 Growth hormone and estrogen are essential for controlling height GH and estrogen are therapeutically used to control height. 6, 72 Recombinant human GH is used to accelerate growth and increase height as a treatment for short stature. 6 Conditions approved for GH therapy include GH deficiency as well as Turner's syndrome, chronic renal insufficiency, small for gestational age, PraderWilli syndrome or idiopathic short stature. 6 In contrast, estrogen is an approved therapy for inhibiting further linear growth for patients with acromegaly (enlargement of extremities caused by excess GH production by the pituitary gland) or other causes of tall stature in girls. 72 Compared to recombinant GH, alternative approaches by using gene therapy in vivo or ex vivo may provide significant advantages for GH therapy by eliminating the need for frequent injections, reducing the costs of the treatment and possibly providing an approach for hormone delivery mimicking the natural process. 73 Using strategies involving intravenous or intramuscular delivery of an adenovirus vector expressing GH, correction of growth deficiency and body composition was demonstrated in GH-deficient mice and an increase in body weight indicative of phenotype correction in dwarf mice, respectively. 73 Successful treatment of hypophysectomized mice (a model of GH deficiency) has been shown by intravenous administration of GH plasmid DNA. 73 Hair follicle is a target for modulation of hair growth and color By being readily accessible at the surface of the body, the hair follicle is an ideal target for gene therapy for hair follicle-associated diseases and for enhancement of hair growth. [74] [75] [76] Targeting of the hair follicle has been demonstrated by delivery of liposome-DNA complexes, 74, 75 plasmid-coated gold particles by using a gene gun (a 400-pounds per square inch helium pulse to accelerate plasmid-coated gold particles through cell membranes), and adenovirus-mediated transgene expression. 47 In a report from 2004 by Yang et al., a change in hair color due to skin depigmentation in rats was achieved by delivery of agouti signaling protein cDNA into the skin by using the gene gun method. The change in depigmentation was the most prominent on day 14 and gradually decreased by day 28. Accelerated hair growth due to activation of hair follicle cycling was demonstrated by intradermal administration of an adenovirus encoding Sonic hedgehog (Shh), a developmental morphogen, and adenovirus-mediated Shh delivery was successfully used to treat chemotherapyinduced alopecia in mice. Greater efficacy was observed when adenovirus was used to deliver a modified form of Shh that lacks cholesterol leading to an expanded range of its diffusion (Figure 2 ). 47 The proof-of-principle of skin-targeted gene therapy in humans was demonstrated in a patient with junctional epidermolysis bullosa, a blistering condition caused by a mutated laminin 5 gene. 77, 78 Ex vivo retroviral transduction of the patient's keratinocytes with laminin 5 followed by transplantation resulted in normal levels of laminin 5 and correction of the skin phenotype within the graft for 1 year.
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Development of genetic enhancement strategies requires addressing ethical, societal and safety issues
The use of gene therapy as an enhancement therapy involves multiple ethical issues related to both the goal and the mode of therapy. These include concerns regarding modifying the human genome, the distinction between therapy and enhancement, the possible ethical concerns related to enhancement itself, and the risks involved in conducting gene therapy treatments in practice. 4, 7, 8 Given the potential to achieve enhancement of an individual through modification of somatic cells by gene therapy, there is a concern that the enhancement technologies used for genetic modification of somatic cells will be purposely applied to germline cells, 4, 8 leading to acceleration of changes in the human evolution. A second concern relates to the distinction between therapy and enhancement. While therapies are aimed at restoring normal functions, enhancements improve function beyond normal level. Current treatments have, however, changed what is thought to be normal as indicated, for example, by increasing lifespan. 79, 80 Furthermore, therapies and enhancements often present as a continuum and the distinction between the two interventions is not always clear. Finally, enhancements that create inequality among people are ethically concerning. One obvious example is when athletes who use doping compete against those who have not. Also, enhancements may generate inequality on an economic basis, if interventions are costly, and therefore, not available to underprivileged groups or societies. As in the case of any other technology, society will ultimately have the responsibility of deciding how and where the technology will be used.
Because there are risks involved with gene therapy, risk/benefit issues are highly relevant regarding enhancement gene therapy. All new treatments pose a some degree of risk, and gene therapy may induce additional risks due to the mode of delivery, often using viral vectors. 7 The additional risks in gene therapy treatments relate to the fact that the drug (transgene) and the carrier (vector) have independent toxicities. The carrier toxicities may include inflammatory or hematologic responses, whereas the drug toxicities may include inappropriate pharmacokinetics, insertional mutagenesis and immunological responses. One of the main goals of further research in the field of gene therapy will be to minimize these risks in favor of benefits. At present, the risks of gene therapy appear to be outweighed by the benefits where the therapy is used to treat a disease. Regulatory agencies may set a different standard if enhancement rather than therapy is the goal.
Prospects
Enhancements are likely becoming more common and acceptable in the future. Already, there are several examples of gene therapy strategies being applied to not only disease treatment, but also enhancement of performance and appearance. Increasing numbers of genetic enhancement strategies will be investigated in different animal models. Concurrently, efficacy and safety of gene therapy technologies will be improved with the aim of developing clinically applicable strategies. Clinical gene therapy trials for treating diseases will precede genetic enhancement trials in humans. In addition, strategies to detect illegal use of genetic enhancement, such as gene doping, will be developed. Evaluation of ethical, societal and regulatory issues regarding genetic enhancement will be imperative before genetic enhancement can become a reality.
Conclusions
The desire to improve performance and appearance is an innate human trait as these qualities are often highly valued in the society. In addition to several conventional therapies currently approved to enhance performance and appearance, there are increasing numbers of studies by using gene therapy approaches not only to treat illnesses, but also to enhance endurance, muscle mass, memory, weight control, or hair and skin qualities. The combination of developing technology of genetic modification and the wish to improve performance and appearance pose important ethical, societal and regulatory issues that need to be acknowledged to maintain the principles of bioethics-autonomy, beneficence, nonmaleficence and justice-and need to be overcome before genetic enhancement can become a reality. 
